Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The vanguard phase of the Low dose ColchicinE in pAtients with peripheral Artery DiseasE to
address residual vascular Risk (LEADER-PAD) trial will evaluate the feasibility of conducting
a full randomized trial to determine if anti-inflammatory therapy with colchicine will reduce
vascular events in patients with symptomatic peripheral artery disease.